PNC-27 is a synthetic peptide (a short chain of amino acids) developed as an experimental anti-cancer agent. It’s designed to target and kill cancer cells while leaving normal, healthy cells unharmed.
How it works:
Cancer cells often display a protein called HDM-2 (also known as MDM-2) on their outer membrane (something normal cells typically don’t do, or do at very low levels). PNC-27 is built from two main parts:
• A section copied from the p53 protein (a natural tumor suppressor), specifically the part that binds to HDM-2 (amino acids 12-26).
• A “membrane-penetrating” or leader sequence that helps the peptide enter or interact with cell membranes.
When PNC-27 encounters a cancer cell:
1. It binds tightly to the HDM-2 on the cell’s surface.
2. This binding causes multiple PNC-27 molecules to cluster and form pores (tiny holes) in the cancer cell’s membrane.
3. These pores lead to rapid leakage of the cell’s contents, causing necrosis (bursting and death of the cell) rather than programmed cell death (apoptosis).
This process is p53-independent, meaning it works even in cancers where the p53 gene is mutated or missing. Lab studies (in cell cultures and animal models like mice) have shown it kills various cancer types, including breast, pancreatic, lung, colon, leukemia, cervical, and others, often at low doses, with no apparent harm to normal cells.
PNC-27 is a synthetic peptide (a short chain of amino acids) developed as an experimental anti-cancer agent. It’s designed to target and kill cancer cells while leaving normal, healthy cells unharmed.
How it works:
Cancer cells often display a protein called HDM-2 (also known as MDM-2) on their outer membrane (something normal cells typically don’t do, or do at very low levels). PNC-27 is built from two main parts:
• A section copied from the p53 protein (a natural tumor suppressor), specifically the part that binds to HDM-2 (amino acids 12-26).
• A “membrane-penetrating” or leader sequence that helps the peptide enter or interact with cell membranes.
When PNC-27 encounters a cancer cell:
1. It binds tightly to the HDM-2 on the cell’s surface.
2. This binding causes multiple PNC-27 molecules to cluster and form pores (tiny holes) in the cancer cell’s membrane.
3. These pores lead to rapid leakage of the cell’s contents, causing necrosis (bursting and death of the cell) rather than programmed cell death (apoptosis).
This process is p53-independent, meaning it works even in cancers where the p53 gene is mutated or missing. Lab studies (in cell cultures and animal models like mice) have shown it kills various cancer types, including breast, pancreatic, lung, colon, leukemia, cervical, and others, often at low doses, with no apparent harm to normal cells.
Image 1 of 1